Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Immune-Modulating Radiation With Durvalumab (MEDI4736) Prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma (RADIANT)

NCT04543110 is registered in ClinicalTrials.gov with Ottawa Hospital Research Institute as lead sponsor.

NCT NCT04543110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04543110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Immune-Modulating Radiation With Durvalumab (MEDI4736) Prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma (RADIANT)
Lead sponsor
Ottawa Hospital Research Institute
Phase
Phase 2
Overall status
Unknown status
Start date
January 29, 2021
Completion date
November 30, 2024
Enrollment
16 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer